**Kroger’s Q3 identical sales without fuel remain under pressure from cautious consumer spending and lingering headwinds.** Second-quarter results showed just 0.2% growth, weighed down by roughly 140 basis points from the Inflation Reduction Act’s pharmacy impact, plus cyclospora-related produce weakness and egg deflation. Management lowered full-year guidance to 0.2–0.8% while keeping earnings targets intact, noting Q3 should edge ahead of Q4 but will still face some residual effects and tougher year-ago comparisons. With the two leading market outcomes (0–0.5% and 0.5–1%) nearly tied, traders are pricing modest sequential improvement against ongoing macro caution and competitive pressure from discounters.